2Marcus L S,Hart D,Packer M,et al.Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure.Adouble-blind.placebo-controllek.randomized crossover trial[J].Circulation,1996,94(2):3184-3189.
3Damman K,Navis G,Smilde T D,et al.Decreased cardiac output,venous congestion and the association with renal impairment in patients with cardiac dysfunction[J].Eur J Heart Fail,2007,9(4):872-878.
4Lenz T L,Foral P A,Malesker M A,et al.Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure[J].Pharmacotherapy,2004,24(9):1137-1146.
5Clyde W,Yancy M D,John C,et al.Decompensated Heart Failure:Is There a Role for the Outpatient:Clinical Implications for Outpatient Use of Nesiritide[J].J Am Coll Cardiol,2004,10(5):230-236.
4Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26: 384-416.
5Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 : the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC ( HFA ) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J, 2008, 29 : 2388-2442.
6Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines ( Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure ). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart fa/lure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ( Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol, 2005, 46: e1-e82.
7Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Aduks: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 2009, 119: 1977-2016.
8Liang KV, Williams AW, Greene EL, et al. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med, 2008, 36(1 Suppl) : S75-S88.
9Chen D, Assad-Kottner C, Orrego C, et al. Cytokines and acute heart failure. Crit Care Med, 2008, 36(1 Suppl) : S9-S16.
10Chen AA, Wood MJ, Krauser DG, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J, 2006, 27 : 839-845.
1Morelli A, Teboul JL. Effects of levosimeudan on systemic and regional hemodynamics in septic myocardial depression [ J ]. Intensive Care Med,2014,32 (5) :791-792.
2Rognoni A, Lupi A, Lazzero M. Levosimendan:from basic science to clinical trials [ J]. Recent Pat Cardiovasc Drug Discov, 2011,5 (2) :315-316.
3Egan JR, Clarke A J, Wiluams S, et al. Levosimendan for lowcardia coutputape diaffice experience [ J ]. Intensive Care Med, 2013,21 (3) :183-187.
